Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension

NCT00046163 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00046163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension
Lead sponsor
Shire
Phase
Phase 4
Overall status
Terminated
Start date
September 5, 2002
Completion date
August 6, 2003
Enrollment
150
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypotension, orthostatic